Keywords: novartis/genentech, file, olizumab, novartis, genentech, presented, first
Novartis/Genentech to file for olizumab
Article | 09 March 2000
Novartis and Genentech have presented the first Phase III clinical datafrom trials of their anti-IgE monoclonal antibody olizumab (rhuMAb-E25), showing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
